Colorectal Cancer

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.

Results from a phase 1/2 study showed that a combination of encorafenib, cetuximab, and nivolumab was well tolerated and yielded promising responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.

Pembrolizumab, binimetinib , and bevacizumab led to deep and durable responses for patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Patients with KRAS-mutant metastatic colorectal cancer who were treated with a combination containing onvansertib had a tolerable safety profile.

Richard Kim, MD, and Lilliana Bustamante, MD, discuss the potnetial for using ctDNA to treat patients with oligometastatic colorectal cancer.

Phase 3 data indicated that primary tumor resection followed by systemic treatment produced higher 60-day mortality vs systemic treatment alone for patients with metastatic colorectal cancer.

Patients with advanced rectal cancer who were treated with up-front chemoradiotherapy plus consolidation chemotherapy experienced an improvement in pathological complete response without impacting disease-free survival.

Arfolitixorin was granted a fast track designation by the FDA for advanced colorectal cancer based on its potential to address unmet medical needs.

Drs Liliana Bustamante and Richard Kim react to limitations surrounding biomarkers used in colorectal cancer and consider how to best study the role of ctDNA moving forward.

Patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer treated with first-line nivolumab plus low-dose ipilimumab experienced a durable clinical benefit.

The potential impact that conclusions highlighted in a recent paper on postoperative MRD analysis in colorectal cancer may have on the management of patients with GI cancers.

Patients who had a poor pathological response to preoperative chemoradiation for advanced rectal cancer and waited 8 weeks or longer for surgery were likely to experience poor overall disease-free survival after completing neoadjuvant chemoradiotherapy.

Following presentation of a paper by Loupakis F, et al., Drs Liliana Bustamante and Richard Kim raise questions pertaining to the use of ctDNA as a biomarker when managing patients with metastatic colorectal cancer undergoing resection.

Despite not meeting its primary end point of superior progression-free survival, the phase 3 SOLSTICE trial’s secondary end point analysis will continue in patients with unresectable metastatic colorectal cancer being treated with trifluridine/tipiracil and bevacizumab.

An overview of what is currently understood about the use of ctDNA assays to help guide treatment decisions when managing patients with colorectal cancer undergoing resection of metastases.

Takayuki Yoshino, MD, PhD gives his perspective on the COLMATE trial and what it's done to help patients overcome colorectal cancer.

Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.

Drs Liliana Bustamante and Richard Kim explore conclusions highlighted by a paper on postoperative MRD analysis as a strong prognostic biomarker in colorectal cancer.

Patients with colorectal liver metastases who were treated with transarterial Yttrium-90 radioembolization plus second-line chemotherapy experienced a long-term survival benefit.

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” by Loupakis F, et al.

Investigators believe that active monitoring presents an alternative option to capecitabine maintenance therapy for patients with stable or responding metastatic colorectal cancer.

The FDA has expanded the label for cetuximab/encorafenib for the treatment of patients with previously treated BRAF V600E–positive metastatic colorectal cancer.

An association was seen between baseline HER2 expression levels and the antitumor activity of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive, metastatic colorectal cancer.

Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.

Adavosertib demonstrated a 65% risk reduction in disease progression and death for patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Data from the KRYSTAL-1 trial show promise of adagrasib as monotherapy and in combination with other standard agents for colorectal cancer.

Patients with colorectal cancer could benefit from the COLMATE platform as it allows for opportunities in clinical trial enrollment.

The use of onvansertib in combination with standard-of-care chemotherapy had an increase in the objective response rate and progression-free survival during the phase 1b/2 trial for metastatic colorectal cancer.

The combination of standard chemoradiotherapy plus avelumab demonstrated clinical activity while maintaining a tolerable safety profile for patients with locally advanced rectal cancer.